Evidence-based perspectives on Mesenchymal Stem Cell therapy, regenerative medicine, and the technologies redefining how we age — curated by the VELAR clinical team.
From ethically sourced Wharton's jelly to Certificate of Analysis release — walk through every stage of how clinical-grade Mesenchymal Stem Cells are cultivated, verified, and prepared for therapy.
Read the full story →
How MSCs target the neuroinflammatory roots of chronic tinnitus — an evidence-based review of cochlear and auditory pathway regeneration.
How MSCs promote tendon repair, collagen regeneration, and inflammation resolution — an evidence-based look at regenerative treatment for chronic tendinopathy.
How MSCs degrade bone marrow fibrosis, suppress aberrant megakaryocyte cytokine signaling, and restore hematopoietic niche architecture.
How MSCs target anti-RBC autoantibodies, complement-mediated hemolysis, and impaired erythropoiesis for durable hematologic remission.
How MSCs restore platelet counts through multi-level immunomodulation, anti-platelet antibody suppression, and megakaryopoiesis support.
How MSCs may target tau/TDP-43 pathology through immunomodulation and progranulin enhancement in FTD.
How MSCs may target autoantibody-driven autonomic dysfunction in Postural Orthostatic Tachycardia Syndrome.
How MSCs may protect kidney podocytes, reduce proteinuria, and restore glomerular filtration in FSGS, MCD, and membranous nephropathy.
How MSCs target fibrotic smooth muscle tumors through ECM remodeling and TGF-β antagonism.
How MSCs target tau pathology and chronic neuroinflammation in CTE — the progressive neurodegenerative disease linked to repetitive head impacts.
How MSCs stabilize mast cells, expand Tregs, and restore immune tolerance in antihistamine-resistant chronic urticaria.
How MSCs recalibrate autoimmune kidney inflammation in lupus — immunomodulation, Treg expansion, and renal protection mechanisms.
How MSCs target chronic colonic mucosal inflammation in collagenous and lymphocytic colitis — mechanisms, evidence, and honest limits.
How MSCs modulate the autoimmune attack on peripheral nerves, promote remyelination, and support long-term recovery in chronic inflammatory demyelinating polyneuropathy.
How MSCs target the chronic neuroinflammation behind persistent concussion symptoms — restoring cerebral blood flow, synaptic protection, and cognitive recovery.
How MSCs target chronic colonic inflammation in diverticular disease — mechanisms, clinical evidence, and honest limitations for reducing flare frequency.
How MSCs may address the dual inflammatory-degenerative pathology of IBM, the most common acquired muscle disease in adults over 50.
How MSCs target the underlying tissue damage in chronic radiation proctopathy — anti-inflammatory, pro-angiogenic, and anti-fibrotic mechanisms for rectal bleeding after radiotherapy.
How MSCs suppress nerve root inflammation, calm dorsal root ganglion hyperexcitability, and support axonal regeneration for the pinched nerve of the neck.
How MSCs promote vascular regeneration and reverse radiation-induced bladder fibrosis after pelvic radiotherapy.
How MSCs target IL-6-driven inflammation in PMR, with the potential to reduce corticosteroid dependence.
How MSCs restore the bone marrow niche, suppress inflammatory cytokines, and re-establish effective hematopoiesis in MDS.
How MSCs support cerebral angiogenesis, neuroprotection, and microvascular repair in vascular cognitive impairment.
How MSCs remodel dermal collagen, restore MMP/TIMP balance, and rebuild skin architecture in atrophic acne scars.
How MSCs protect the endothelium, restore nitric oxide, and reduce vaso-occlusive crises in sickle cell disease.
How MSCs target the gut-liver immune axis, suppress periductal concentric fibrosis, and preserve bile duct architecture in PSC.
How MSCs target the TGF-β/Smad fibrotic cascade, suppress myofibroblast persistence, and promote scarless healing.
How MSCs target the immune dysregulation driving IgA nephropathy — B-cell modulation, Treg restoration, complement inhibition, and podocyte protection.
How MSCs target spinal cord inflammation, promote remyelination, and support recovery after an immune-mediated attack on the spinal cord.
How MSC therapy targets the innate immune drivers of rosacea — TLR2/cathelicidin signaling, angiogenesis dysregulation, and mast cell-mediated facial inflammation.
How MSC therapy targets the underlying pathology of optic neuritis — immunomodulation, neuroprotection, and remyelination support for the optic nerve.
How MSC therapy targets the root drivers of diabetic kidney disease — glomerular inflammation, podocyte injury, and tubulointerstitial fibrosis — and what early-phase trials reveal.
Wound Care
How MSCs promote angiogenesis, reduce inflammation, and shift the wound microenvironment from chronic deterioration toward active regeneration.
Surgery
How MSCs target peritoneal adhesions through fibrinolytic restoration and TGF-β suppression — breaking the cycle of surgery and scar formation.
How MSCs may calm the Th2 immune attack driving eosinophilic esophagitis and support anti-fibrotic esophageal healing.
How MSCs may calm the autoimmune attack on muscle in inflammatory myopathy and support muscle-fiber repair.
How MSCs target inflammation, cartilage degradation, and disc pathology in the temporomandibular joint.
A complete guide to finding, evaluating, and enrolling in registered MSC clinical trials — eligibility, consent, costs, and red flags.
How MSCs target cyst epithelial proliferation and renal fibrosis in PKD — preclinical evidence, mechanisms, and honest limitations.
How MSCs target the CD8+ T-cell attack on basal keratinocytes to restore immune tolerance at the dermal-epidermal junction.
How MSCs target immune dysregulation in glomerular disease — Treg induction, macrophage polarization, and proteinuria reduction.
A comprehensive guide to the global regulatory landscape for MSC therapy — FDA, EMA, PMDA, Thai FDA, and more.
How MSC therapy enhances muscle repair, mitochondrial efficiency, and injury prevention — evidence-based protocols for elite athletic recovery.
How MSCs target the inflammatory drivers of HS — follicular occlusion, IL-1β, and tunneling disease.
Which MSC source to store — a data-driven comparison of viability, expansion potential, and clinical applications for cord blood, Wharton's jelly, and adipose banking.
When does a second MSC infusion add value? Half-life of effects, tachyphylaxis risk, and cost-benefit analysis for chronic vs acute conditions — an evidence-based treatment frequency guide.
How MSC therapy works synergistically with PRP, exosomes, pharmaceuticals, and rehabilitation — evidence-based combination protocols for enhanced regenerative outcomes.
How MSC therapy is being studied for cerebral palsy, autism, HIE, and other childhood conditions — neuroprotection, immunomodulation, and developmental repair.
The evidence behind cell-count protocols — per-kg vs fixed-dose, route-specific dosing, safety ceilings, and how to evaluate dose claims critically.
How MSCs restore ICC networks, protect enteric neurons, and improve gastric emptying.
The documented warning signs — from fake credentials to high-pressure sales — that separate legitimate clinics from dangerous operators.
How MSCs combat tumor-driven muscle wasting by suppressing inflammatory cytokines, protecting the Akt/mTOR pathway, and restoring mitochondrial function — an evidence-based review.
How MSCs target myofibroblast-driven palmar fibrosis, suppress TGF-β signaling, and restore hand function in Dupuytren's disease — an evidence-based review.
Evidence-based MSC protocols for healthspan optimization — targeting cellular aging, mitochondrial renewal, and biological age reversal through regenerative biohacking.
How MSCs support extracellular matrix remodeling, reduce chronic pain, and strengthen connective tissue in EDS — an evidence-based review of mesenchymal stem cell therapy for genetic collagen disorders.
How MSCs reduce neuroinflammation, protect neural elements, and address spinal canal narrowing — an evidence-based review.
MSC-mediated clotting factor delivery, inhibitor prevention, and joint protection for hemophilia A and B complications.
MSC hematopoietic support, iron overload mitigation, and HSCT engraftment enhancement for genetic hemoglobinopathy complications.
How MSCs may reduce vertigo attacks, protect cochlear hair cells, and support spiral ganglion neurons in Meniere's disease.
How MSCs may restore hepatic immune tolerance, expand regulatory T cells, and reduce hepatocyte destruction in autoimmune hepatitis.
How MSCs may suppress desmoglein-specific B cells, restore Treg/Th17 balance, and promote re-epithelialization in autoimmune blistering disease.
Gut-brain axis, visceral hypersensitivity, and MSC-mediated intestinal barrier repair.
How MSCs target neutrophilic airway inflammation, biofilm disruption, and epithelial repair in chronic bronchiectasis — preclinical rationale and clinical status.
How MSCs deliver neurotrophic factors, reduce retinal inflammation, and preserve photoreceptors in inherited retinal degeneration — early evidence and honest expectations.
How MSCs target neuroinflammation, suppress glial activation, and promote neurotrophic repair in CRPS — early evidence and limitations.
How MSCs suppress the perifollicular CD8+ NKG2D+ T-cell attack, expand regulatory T cells, and restore hair follicle immune privilege — early evidence for autoimmune hair loss.
A comprehensive framework for evaluating stem cell clinics — from physician credentials and lab accreditation to cell sourcing, pricing transparency, and structured follow-up.
How MSCs may recalibrate intraocular immune responses, protect retinal neurons, and promote Treg expansion — early evidence for refractory autoimmune eye disease.
How MSCs may recalibrate the Th17/Treg imbalance driving systemic vasculitis, oral ulcers, and uveitis — early clinical evidence and honest limitations.
How MSCs may calm airway inflammation, combat chronic infection, and support lung tissue repair in CF — an evidence-based clinical perspective with 18 references.
How MSCs promote alveolar bone repair, periodontal ligament regeneration, and cementum formation — a regenerative approach to gum disease and tooth-supporting tissue loss.
How MSCs may protect cochlear hair cells and support auditory neurons in presbycusis — from spiral ganglion preservation to realistic clinical expectations.
How MSC-sprayed wound beds accelerate re-epithelialization, reduce hypertrophic scarring, and regenerate functional skin after deep burn injury.
Nanoscale signaling vesicles or intact living cells — a balanced comparison of two MSC-based approaches, their mechanisms, and when each makes sense.
When the blood-brain barrier matters — how CSF pharmacokinetics compare to first-pass lung trapping, and which route the evidence favors for neurological vs systemic conditions.
How MSCs target neuroinflammation, restore hippocampal neurogenesis, and support cognitive recovery after chemotherapy — from preclinical models to emerging clinical evidence.
How MSCs target scar, angiogenesis, and LVEF in ischemic heart disease — what POSEIDON, DREAM-HF, and other trials show.
How MSCs target hippocampal sclerosis, preserve GABAergic interneurons, and reduce seizure frequency in drug-resistant MTLE — from preclinical models to early clinical evidence.
How MSCs restore disc height, promote nucleus pulposus regeneration, and reduce chronic low back pain — from preclinical models to phase III clinical trial evidence.
How MSCs interrupt the neuroinflammatory pain cycle in CPPS — macrophage polarization, NGF suppression, and emerging clinical evidence for pelvic floor immunomodulation.
How periurethral MSC injection regenerates the urethral sphincter — myogenic differentiation, angiogenesis, and the clinical evidence.
How MSCs suppress autoreactive T-cell clones, reconstruct the hematopoietic niche, and restore bone marrow function through coordinated immunomodulation and paracrine support.
How MSCs reverse laryngeal fibrosis through TGF-β antagonism, MMP-mediated collagen degradation, and hyaluronic acid restoration — restoring the mucosal wave for voice recovery.
How MSC engraftment introduces healthy, collagen-producing osteoblasts to improve bone density and reduce fracture frequency in brittle bone disease — from Horwitz to Le Blanc.
How MSCs target the inflammatory and microvascular pathology of chronic venous wounds — macrophage polarization, angiogenesis, and ECM remodeling for durable closure.
How MSCs target arrested alveolar development in bronchopulmonary dysplasia — anti-inflammatory protection, VEGF-driven angiogenesis, and alveolar regeneration for improved respiratory outcomes.
How MSCs target the secondary inflammatory cascade in hypoxic-ischemic encephalopathy — neuroprotection, mitochondrial rescue, and myelination support for improved neurodevelopmental outcomes.
How MSCs rebuild the endometrium after intrauterine adhesions — progenitor cell replenishment, fibrosis reversal, and angiogenesis for restored fertility.
How MSCs target the basement-membrane defect in EB — paracrine wound repair, collagen VII restoration, and inflammation control for fragile skin.
How locally injected MSCs close complex perianal fistulas — the evidence from ADMIRE-CD and EMA-approved darvadstrocel.
How MSC therapy targets cellular senescence, SASP reduction, mitochondrial renewal, and epigenetic reprogramming for healthier aging.
How MSCs target neurovascular pathology — pericyte replacement, BBB repair, and white-matter protection for CSVD.
How MSCs interrupt the autoimmune-fibrotic loop — Th1/Th17 suppression, Treg expansion, and reversal of chronic fibrotic scarring.
How MSCs target type 2 inflammation, suppress nasal polyp recurrence, and restore sinonasal barrier function.
How MSC therapy targets retinal microvascular damage and pericyte loss — a regenerative approach to preserving vision in diabetic eye disease.
How MSCs target TGF-β-driven fibrotic plaques through collagen degradation, myofibroblast apoptosis, and tissue remodeling — a disease-modifying approach to penile curvature.
How MSCs target neutrophilic inflammation, defective wound healing, and immune dysregulation in this rare ulcerative skin disease.
How MSCs target post-radiotherapy scarring through TGF-β suppression, decorin-mediated collagen remodeling, and microvascular restoration.
How MSCs suppress the pancreatic inflammatory cascade, reprogram macrophages, protect distant organs, and promote acinar regeneration — the emerging evidence.
How MSCs protect retinal ganglion cells, deliver neurotrophic factors, and modulate microglia — the neuroprotective paradigm studied for optic nerve preservation.
How MSCs suppress neuroinflammation, reprogram microglia from M1 to M2, promote remyelination, and preserve spinal cord function in cervical myelopathy — preclinical evidence, delivery strategies, and honest limitations.
How MSCs combat chronic bone infection — antimicrobial peptide secretion disrupts biofilms, immunomodulation resolves inflammation, and osteogenic differentiation rebuilds the bone defect — the evidence from preclinical and clinical research.
How MSCs may restore immune tolerance in PBC, preserve bile duct architecture, and inhibit hepatic fibrosis — early clinical evidence, mechanisms, and honest limitations.
How MSCs promote lymphangiogenesis through VEGF-C secretion, reduce chronic inflammation, and remodel fibrotic tissue — early clinical evidence, mechanisms, and honest limitations.
How MSCs suppress the immune attack on blood vessel walls — Treg expansion, M1→M2 macrophage polarization, endothelial repair, and the emerging clinical evidence in ANCA-associated vasculitis.
How MSCs may relieve post-shingles nerve pain through paracrine immunomodulation, neurotrophic factor secretion, and neural repair — the preclinical rationale and emerging clinical evidence.
How MSCs restart stalled wound healing in chronic diabetic ulcers — angiogenesis, M1-to-M2 macrophage polarization, re-epithelialization, and clinical evidence for non-healing DFUs.
How MSCs promote new blood vessel growth in no-option CLI — the science, clinical evidence, and honest limitations of angiogenic cell therapy for limb salvage.
How MSCs may restore gluten tolerance, repair the intestinal epithelium, and suppress gliadin-reactive T cells — the preclinical rationale and early evidence.
How MSCs suppress tubular apoptosis, polarize macrophages, transfer mitochondria, and attenuate the AKI-to-CKD transition — the evidence from preclinical and early clinical research.
How MSCs suppress cardiac inflammation, reduce myocardial fibrosis, promote angiogenesis, and preserve ejection fraction — the evidence from preclinical and early clinical research.
How MSCs modulate the cytokine storm, protect the endothelium, reprogram macrophages, and enhance bacterial clearance — the evidence from preclinical and early clinical research.
How MSCs restore ovarian function through immunomodulation, anti-apoptosis, angiogenesis, and paracrine signaling — the evidence from preclinical and early clinical research.
How MSCs modulate cytokine storm, restore alveolar-capillary barrier integrity, and promote lung repair — the evidence from preclinical models and clinical trials.
How MSCs target hepatic steatosis, inflammation, and early fibrosis — a multi-pathway approach to the world's most common chronic liver disease.
How MSCs suppress donor T-cell attack in GvHD — the only MSC indication with regulatory approval across 3 continents.
How MSCs target the vascular inflammation, endothelial dysfunction, and smooth muscle proliferation driving PAH.
How MSCs combat age-related muscle loss through myogenesis, inflammation reduction, and mitochondrial repair.
How MSCs deliver BDNF, reduce striatal neuroinflammation, and protect medium spiny neurons — the preclinical evidence.
How MSCs reduce neuroinflammation, promote myelin repair, and modulate pain signaling in the trigeminal nerve — the honest evidence.
How MSCs suppress granuloma formation, modulate the Th1/Th17 response, and reduce pulmonary inflammation in sarcoidosis through paracrine immunomodulation.
The cellular biology of fracture repair and how MSCs promote callus formation, osteogenic differentiation, and bone regeneration in non-union fractures.
How MSCs promote facial nerve repair, remyelination, and functional recovery in Bell's palsy through neurotrophic factor secretion and immunomodulation.
How MSCs promote tendon regeneration, collagen repair, and inflammation resolution in chronic lateral epicondylitis.
How MSCs repair the bladder lining, suppress mast cell-driven neuroinflammation, and reduce pelvic pain in IC/BPS.
How MSCs suppress the IL-23/IL-17 axis driving spinal inflammation, reduce disease activity, and may slow structural progression in AS.
How MSCs modulate the immune attack on peripheral nerves, promote remyelination, and accelerate neurological recovery after GBS.
How MSCs target the Th2-driven inflammatory cascade, rebalance immune dysregulation, and promote epidermal barrier restoration for chronic eczema.
How MSCs reduce neuroinflammation at compressed nerve roots — from chemical radiculitis to transforaminal epidural delivery and realistic recovery timelines.
How MSCs target the NLRP3 inflammasome and IL-1β cascade in MSU crystal-driven arthritis — from urate-lowering limitations to early clinical signals.
How MSCs stimulate angiogenesis and arteriogenesis in ischemic limbs — from preclinical limb salvage to clinical trials in no-option critical limb ischemia.
How MSCs target Th2-driven airway inflammation, expand regulatory T cells, and may offer disease-modifying potential for severe, treatment-resistant asthma.
How MSCs target disc degeneration at the cellular level — reducing inflammation, stimulating matrix synthesis, and preserving disc height in chronic low back pain.
How MSCs promote median nerve repair, remyelination, and functional recovery in carpal tunnel syndrome — an evidence-based review.
How MSCs promote tendon repair, collagen regeneration, and functional recovery in chronic Achilles tendinopathy — an evidence-based review.
How MSCs are being studied for fascia repair, collagen regeneration, and chronic heel pain relief — an evidence-based review of the clinical data.
How MSC therapy targets neuroinflammation, protects neurons, and supports neural repair after traumatic brain injury — an evidence-based review of preclinical research through early clinical data.
How MSC therapy targets the vascular, neurogenic, and endothelial roots of erectile dysfunction — an evidence-based guide from preclinical research to early clinical data.
How MSC therapy restores blood supply and promotes bone regeneration in osteonecrotic joints — an evidence-based guide from early-stage intervention to hip preservation.
How MSC therapy targets the inflammation and fibrosis driving frozen shoulder — an evidence-based guide to non-surgical treatment for adhesive capsulitis.
How MSCs target neuroinflammation, immune dysregulation, and mitochondrial failure — the honest evidence from preclinical and early clinical research.
How MSCs target the fibrotic cascade through HGF, KGF, and immunomodulation — early clinical evidence and honest limitations.
What clinical trials involve, how to find legitimate studies, eligibility criteria, informed consent, and what to expect at every stage of research participation.
Compare FDA, EMA, PMDA, TFDA and other regulatory frameworks — what patients should know before seeking MSC treatment abroad.
How MSC therapy supports mitochondrial efficiency, recovery, and inflammation control for elite athletes.
How MSC therapy is being studied for cerebral palsy, autism, BPD, and genetic conditions — the evidence, safety considerations, and what families should know.
How MSCs target the hallmarks of aging — from epigenetic clocks to mitochondrial repair — and what the evidence supports.
How cryopreservation stores your youngest MSCs for the therapies of tomorrow — science, standards, and what to know before banking.
How MSCs may restore immune tolerance at the neuromuscular junction and reduce pathogenic autoantibodies.
How MSCs may preserve residual beta-cell function and modulate the autoimmune attack in Type 1 Diabetes.
How MSCs may calm the autoimmune attack on melanocytes and restore skin pigmentation.
How MSCs may reset immune tolerance in Graves' — calming thyroid overdrive and orbital inflammation at the autoimmune source.
How MSCs may restore immune tolerance and preserve thyroid function in Hashimoto's — targeting the autoimmune process itself.
How MSCs may quiet the autoimmune attack on salivary and lacrimal glands, restoring moisture at the tissue level.
A structured framework for evaluating any stem cell clinic — laboratory standards, physician credentials, red flags, and the questions that reveal quality.
How MSCs work best as part of a coordinated strategy — with PRP, exosomes, peptides, NAD+, and evidence-based rehabilitation protocols.
How many millions of cells per kilogram? What clinical evidence says about dose-response — and why the number matters more than patients realize.
MSC therapy and PRP are not interchangeable — one rebuilds tissue, the other accelerates healing. An evidence-based comparison of when each approach makes clinical sense.
How MSCs target colonic inflammation at its source — modulating immunity and restoring the epithelial barrier.
How MSCs promote tendon repair, collagen regeneration, and functional recovery in chronic tendinopathy.
How MSC therapy supports collagen remodeling, fibroblast activation, and dermal regeneration — a clinical guide to regenerative aesthetics.
How MSC therapy targets the autoimmune-driven fibrosis at the core of scleroderma — from skin thickening to organ involvement.
How MSC therapy supports tendon-to-bone healing in partial and full-thickness rotator cuff tears — with 15 cited references.
How MSC therapy targets chronic inflammation, insulin resistance, and ovarian fibrosis in polycystic ovary syndrome — with 19 cited references.
How MSC therapy targets the IL-23/Th17 axis and calms keratinocyte hyperproliferation in psoriatic disease — with 19 cited references.
How MSC therapy targets the inflammatory-fibrotic cascade in Duchenne, Becker, LGMD, and FSHD — with 18 cited references.
How MSC therapy targets neuroinflammation, blood-brain barrier integrity, and trigeminal pain pathways in migraine — with 18 cited references.
How MSC therapy supports ovarian follicle regeneration, spermatogenesis restoration, and endometrial repair — with 20 cited references.
How MSC therapy supports retinal pigment epithelium survival and modulates neuroinflammation in age-related macular degeneration — with 15 cited references.
How MSC therapy repairs meniscus tears and cartilage damage — a regenerative alternative to arthroscopic partial meniscectomy with 18 cited references.
How MSCs support hair cell survival, spiral ganglion neuron protection, and cochlear anti-inflammatory repair — an evidence-based review with 20 cited references.
How MSCs target neuroinflammation, preserve GABAergic neurons, repair the blood-brain barrier, and reduce seizure frequency — an evidence-based review with 20 cited references.
How MSCs may target neuroinflammation, central sensitization, and immune dysregulation — an evidence-based review with 17 cited references.
How MSCs target chronic pelvic inflammation, fibrosis, immune dysregulation, and lesion growth — an evidence-based review with 18 cited references.
How MSCs support alveolar bone repair, gingival tissue regeneration, and periodontal ligament restoration — an evidence-based review with 15 cited references.
How MSCs target pancreatic fibrosis, suppress stellate cell activation, and reduce chronic pain — an evidence-based review with 20 cited references.
How mesenchymal stem cells promote axonal regeneration, remyelination, and neuropathic pain reduction — an evidence-based review with 17 cited references.
How MSC therapy targets neuroinflammation, supports neural repair, and improves motor function in children and adults with cerebral palsy.
How mesenchymal stem cells accelerate re-epithelialization, promote angiogenesis, reduce hypertrophic scarring, and modulate the wound microenvironment — 19 cited references on MSC therapy for burns and chronic wounds.
How MSC therapy may address disc degeneration, reduce spinal inflammation, and support nerve healing — 12 cited references, a science-based look at regenerative options for chronic back pain.
How mesenchymal stem cells may support cartilage repair, reduce intra-articular inflammation, and modulate chondrocyte senescence — 45 cited references covering WOMAC, VAS, MRI outcomes and key RCTs (Vega, Matas, Lamo-Espinosa).
How MSC therapy may address endothelial aging, smooth muscle loss, hormonal decline, and tissue fibrosis — 14 cited references, a science-based look at andropause, menopause, and regenerative options.
How MSC therapy may address the persistent inflammation, immune dysregulation, and endothelial damage behind Long COVID — 17 cited references, an honest look at the early evidence.
A conservative, evidence-based look at how MSC therapy may support sexual health through tissue regeneration and vascular repair — what the early research shows and does not yet show.
How MSC therapy supports tendon, ligament, muscle and cartilage recovery — realistic timelines, candidacy, and what athletes can expect from regenerative treatment.
MSC immunomodulation, regulatory T-cell balance and TNF-α/IL-6/IL-17 — what the umbilical-cord MSC pilot trials and DAS28 data show for refractory rheumatoid arthritis, and the honest limitations.
MSC anti-fibrotic and anti-inflammatory paracrine signalling, VEGF/HGF and the rexlemestrocel-L diabetic-kidney trials — eGFR outcomes and a clear-eyed look at what is still investigational.
MSC anti-fibrotic action on hepatic stellate cells and the decompensated-cirrhosis and ACLF trials — MELD/albumin signals, mixed durability, and an honest account of the limits.
MSC anti-inflammatory action, paracrine lung-repair signaling and the Phase II remestemcel-L trial — the mechanisms, the FEV1/6MWT outcomes, and an honest look at what is still investigational.
Allogeneic umbilical-cord MSC immunomodulation, regulatory T-cell modulation and the Nanjing transplantation trials — lupus nephritis outcomes, SLEDAI scoring, and the honest limitations.
HSCT, MSC immunomodulation and the MIST trial — what the research actually shows for relapsing and progressive MS, and the honest limitations.
Neural stem cells, OPCs and the SCiStar trial — the mechanisms, the ASIA-scale outcomes, and a responsible look at what is still investigational.
How MSC exosomes carry the regenerative signal of stem cells without the cells themselves — the science, the research status, and the honest limitations.
A careful, evidence-based review of where MSC therapy fits — and the responsible boundaries of family expectations.
How MSC therapy supports follicular regeneration in androgenetic alopecia, alopecia areata, and other forms of hair loss.
Where MSC therapy realistically fits in diabetes management — alongside diet, exercise, and standard endocrine care.
MSCs in neurodegenerative care — neuroinflammation, mitochondrial support, alongside standard neurology.
What MSC therapy can — and cannot — do for motor neuron disease. A patient-focused clinical review.
How MSC therapy may support stroke recovery — calming neuroinflammation, protecting at-risk neurons, supporting repair pathways.
Neuroinflammation modulation, neurotrophic factors and the early Phase I safety studies — why no stem cell therapy is a proven treatment for dementia, and how to spot the hype.
The EU-approved darvadstrocel (Alofisel) for perianal fistulas versus investigational systemic therapy — the ADMIRE-CD evidence and the honest line between the two.
MSCs are the natural precursors of bone-forming osteoblasts — the preclinical promise, the sparse human data, and why this is not yet an alternative to proven osteoporosis medicine.
Paracrine repair rather than new heart muscle — POSEIDON and DREAM-HF safety and the mixed endpoints, and an honest read on where MSC therapy for heart failure really stands.
The common mild side effects, the serious risks that trace to unregulated clinics, and why cell type, source and GMP standards decide whether stem cell therapy is safe.
Your own cells versus donor cells — the trade-offs in potency, rejection risk and standardization, and why MSCs are low-immunogenic enough to rarely need HLA matching.
From first consultation and baseline biomarkers to cell preparation, delivery and follow-up — a step-by-step, realistic walk through what a responsible MSC treatment journey involves.
What shapes price, the certifications that matter, and the questions every international patient should ask before booking regenerative medicine.
How MSC therapy modulates the immune system in rheumatoid arthritis, lupus, multiple sclerosis, and other autoimmune disease — without broad immunosuppression.
How MSC therapy targets cellular senescence, mitochondrial decline, and chronic inflammation to influence the underlying drivers of how we age.
How MSC therapy supports cartilage regeneration, reduces joint inflammation, and helps patients regain mobility — with realistic timelines and what to expect.
Compare bone marrow, adipose, and umbilical cord MSC sources — and discover why Wharton's jelly has become the gold standard for clinical-grade therapy.
An evidence-based introduction to MSC therapy — what it is, how it works, who it helps, and what the latest clinical research shows.